July 11, 2017
Weil is advising Sanofi in its up to $750 million acquisition of Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones. The transaction is expected to close in the third quarter of 2017, subject to customary regulatory approvals.
The Weil team advising Sanofi is led by Corporate Chairman Michael Aiello and Corporate partner Shayla Harlev and includes Corporate associates Christina De Vuono, Hayden Guthrie (Not Yet Admitted in New York), Aamir Rahman and Brianna Dollinger (Not Yet Admitted in New York). The team also includes Technology & IP Transactions partner Jeffrey Osterman; Tax partner Chayim Neubort; Executive Compensation & Benefits partner Amy Rubin; Antitrust partner John Scribner; Complex Commercial Litigation partner Yehudah Buchweitz; Antitrust counsel Michael Naughton; Technology & IP Transactions associates Jennifer Yoon and Dennis Adams; Tax associate Scott Fryman; Executive Compensation & Benefits associate Zahava Blumental; and Antitrust associate Christopher Abbott.